Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-Induced Erythroid Precursor-Differentiated Myeloid Cells Mediate Immunosuppression and Curtail Anti-PD-1/PD-L1 Treatment Efficacy

ABSTRACT: Despite the unprecedented success of immune checkpoint inhibitors (ICIs) as anti-cancer therapy, it remains a prevailing clinical need to identify additional mechanisms underlying ICI therapeutic efficacy and potential drug resistance. Here, using lineage tracking in cancer patients and tumor-bearing mice, we demonstrate that erythroid progenitor cells lose their developmental potential and switch to the myeloid lineage. Single-cell transcriptome analyses reveal that, notwithstanding quantitative differences in erythroid gene expression, erythroid differentiated myeloid cells (EDMCs) are transcriptionally indistinguishable from their myeloid-originated counterparts. EDMCs possess multifaceted machinery to curtail T cell-mediated anti-tumor responses. Consequently, EDMC content within tumor tissues is negatively associated with T cell inflammation for the majority of solid cancers; moreover, EDMC enrichment, in accordance with anemia manifestation, is predictive of poor prognosis in various cohorts of patients undergoing ICI therapy. Together, our findings reveal a feed-forward mechanism by which tumors exploit anemia-triggered erythropoiesis for myeloid transdifferentiation and immunosuppression.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE201715 | GEO | 2022/04/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Tumor-Induced Erythroid Precursor-Differentiated Myeloid Cells Mediate Immunosuppression and Curtail Anti-PD-1/PD-L1 Treatment Efficacy

Project description:Tumor-Induced Erythroid Precursor-Differentiated Myeloid Cells Mediate Immunosuppression and Curtail Anti-PD-1/PD-L1 Treatment Efficacy

| PRJNA832746 | ENA

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy [bulkTCRseq]

Project description:Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. We utilized TCR sequencing to identify and track alloreactive T cells in a patient with melanoma who experienced kidney transplant rejection following ICI therapy. ICI therapy was associated with a sharp increase in circulating alloreactive CD8+ T cell clones, many of which were also detected in the rejected kidney but not at tumor sites. Longitudinal and cross-tissue TCR analyses revealed unintended expansion of alloreactive CD8+ T cells induced by ICI therapy for cancer, coinciding with ICI-associated organ rejection.

2023-02-01 | GSE216758 | GEO

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy [MLR single-cell]

2023-02-01 | GSE216756 | GEO

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy [Non-naive CD8 single-cell]

2023-02-01 | GSE216762 | GEO

Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders

Project description:Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, the responses to ICI treatment are highly variable in different individuals and the underlying mechanisms remain poorly understood.

2023-03-17 | GSE227404 | GEO

Entinostat decreases immune suppression to promote an anti-tumor response within a HER2+ breast tumor microenvironment.

Project description:Therapeutic combinations to alter solid tumor microenvironments (TME) in immunosuppressive tumors such as breast cancer are essential to improve their responses to immune checkpoint inhibitors (ICIs). Entinostat, an oral histone deacetylase inhibitor (HDACi), has been shown to improve responses to ICIs in various tumor models with immunosuppressive TMEs. The precise and comprehensive alterations to the TME induced by entinostat remain unknown. Here, we employ single-cell RNA-sequencing on HER2 overexpressing breast tumors from mice treated with entinostat and ICIs to characterize for the first time changes across all cell types within the TME. This analysis demonstrates that treatment with entinostat induces a shift from a pro-tumor to an anti-tumor TME signature characterized predominantly by changes in the myeloid cells. We confirm myeloid-derived suppressor cells (MDSCs) within entinostat-treated tumors are associated with a less suppressive G-MDSC phenotype and now demonstrate altered suppressive signaling involves the NFkB and STAT3 pathways. In addition to MDSCs, tumor-associated macrophages are epigenetically reprogrammed toward an anti-tumor M1-like phenotype likely contributing to a more sensitized TME. Overall, our in-depth analysis suggests entinostat-induced changes on multiple myeloid cell types reduce immunosuppression and increase mechanisms of an anti-tumor response that improve sensitivity to ICI. Sensitization of the TME by entinostat could ultimately broaden the population of patients with breast cancer who could derive benefit from ICIs.

2022-01-18 | GSE166321 | GEO

Intratumoral TFR cells curtail anti-PD-1 treatment efficacy

Project description:Intratumoral TFR cells curtail anti-PD-1 treatment efficacy

| PRJNA547551 | ENA

Intratumoral TFR cells curtail anti-PD-1 treatment efficacy

Project description:Intratumoral TFR cells curtail anti-PD-1 treatment efficacy

| PRJNA607958 | ENA

Impact of brequinar treatment on gene expression in bone marrow progenitors of tumor-bearing mice

Project description:Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology; however, ICIs are effective in subsets of patients. A major limitation of their efficacy is tumor-driven immune suppression, and one key mechanism is the ‘biogenesis’ of myeloid-derived suppressor cells (MDSCs). A fundamental gap in MDSC biology is the dearth of approaches that target their biogenesis. We hypothesized that targeting MDSC biogenesis will mitigate MDSC burden and bolster responses to ICIs. We focused on a class of agents, dihydroorotate dehydrogenase (DHODH) inhibitors, recently found to restore terminal differentiation of leukemic myeloid progenitors and is in clinical trials of AML. One such DHODH inhibitor is brequinar. Using preclinical models of mammary cancer that elicit robust MDSC responses, we demonstrated that brequinar suppressed MDSC biogenesis, enhancing the antitumor and anti-metastatic activity of PD-1-based ICI therapy. In this single-cell RNA transcriptomics study, we sought to determine the impact of brequinar treatment of tumor-bearing mice on altering gene expression in bone marrow myeloid progenitors. Thus, this cutting-edge molecular approach enabled us to test the hypothesis that brequinar acted in the bone marrow at a qualitative level to mitigate MDSC biogenesis.

2022-06-30 | GSE190232 | GEO

Intratumoral TFR cells curtail anti-PD-1 treatment efficacy [human]

Project description:Intratumoral TFR cells curtail anti-PD-1 treatment efficacy [human]

| PRJNA547554 | ENA